Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Oct 1;204(7):1120-4.
doi: 10.1093/infdis/jir486.

Prolonged selection of pfmdr1 polymorphisms after treatment of falciparum malaria with artemether-lumefantrine in Uganda

Frederick N Baliraine  1 , Philip J Rosenthal
Affiliations

Prolonged selection of pfmdr1 polymorphisms after treatment of falciparum malaria with artemether-lumefantrine in Uganda

Frederick N Baliraine et al. J Infect Dis. .

Abstract

We compared the prevalence of key pfmdr1 alleles between pretreatment Plasmodium falciparum parasite isolates and parasites that emerged after treatment of uncomplicated malaria in a longitudinal cohort of Ugandan children. The pfmdr1 86N, 184F, and 1246D alleles were selected after treatment with artemether-lumefantrine, but not after artesunate-amodiaquine or amodiaquine-sulfadoxine-pyrimethamine. Remarkably, selection persisted in infections presenting up to about 60 days after treatment with artemether-lumefantrine. Thus, parasites selected for decreased drug sensitivity can appear long after predicted exposure to antimalarial drugs. Continued surveillance of the clinical efficacy and in vitro activity of new combination therapies is warranted.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Prevalence of pfmdr1 alleles in pretreatment samples and in samples collected after treatment with artemether-lumefantrine in a cohort of children in Kampala, Uganda. For clarity, prevalences of the pure 86Y, 184Y, and 1246Y alleles are not shown. *Significantly higher than pretreatment prevalence by Fisher exact test (2-tailed; P < .05).
See this image and copyright information in PMC

Comment in

References

    1. Stepniewska K, White NJ. Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. Antimicrob Agents Chemother. 2008;52:1589–96. - PMC - PubMed
    1. Mwesigwa J, Parikh S, McGee B, et al. Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. Antimicrob Agents Chemother. 2010;54:52–9. - PMC - PubMed
    1. Dokomajilar C, Nsobya SL, Greenhouse B, Rosenthal PJ. Dorsey G. Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic. Antimicrob Agents Chemother. 2006;50:1893–5. - PMC - PubMed
    1. Happi CT, Gbotosho GO, Folarin OA, et al. Selection of Plasmodium falciparum multidrug resistance gene 1 alleles in asexual stages and gametocytes by artemether-lumefantrine in Nigerian children with uncomplicated falciparum malaria. Antimicrob Agents Chemother. 2009;53:888–95. - PMC - PubMed
    1. Humphreys GS, Merinopoulos I, Ahmed J, et al. Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria. Antimicrob Agents Chemother. 2007;51:991–7. - PMC - PubMed

Publication types

MeSH terms